ACM
IONS icon

AlphaCrest Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

AlphaCrest Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,770
Closed -$653K – 565
2022
Q3 		$653K Sell
14,770
-21,677
-59% -$913K 0.04% 855
2022
Q2 		$1.35M Sell
36,447
-21,845
-37% -$824K 0.07% 520
2022
Q1 		$2.16M Buy
58,292
+5,385
+10% +$176K 0.12% 220
2021
Q4 		$1.61M Buy
52,907
+823
+2% +$25.9K 0.06% 557
2021
Q3 		$1.75M Buy
52,084
+32,724
+169% +$1.23M 0.09% 369
2021
Q2 		$772K Buy
+19,360
New +$758K 0.03% 781
2021
Q1 		– Sell
-4,842
Closed -$274K – 1239
2020
Q4 		$274K Sell
4,842
-7,403
-60% -$369K 0.02% 950
2020
Q3 		$581K Buy
12,245
+3,726
+44% +$207K 0.06% 505
2020
Q2 		$502K Sell
8,519
-12,362
-59% -$688K 0.08% 385
2020
Q1 		$987K Buy
20,881
+15,381
+280% +$857K 0.12% 280
2019
Q4 		$332K Sell
5,500
-5,200
-49% -$310K 0.03% 1009
2019
Q3 		$641K Buy
+10,700
New +$697K 0.04% 794

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AlphaCrest Capital Management's IONS Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2022, closing a stake of 14,770 shares — an estimated $653K sold.

AlphaCrest Capital Management first reported a position in IONS in Q3 2019 and held it in 12 quarters. The position peaked at $2.16M in Q1 2022. 339 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 14,770 Ionis Pharmaceuticals shares in Q4 2022, an estimated $653K.
  • AlphaCrest Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2019 and held it in 12 quarters.
  • AlphaCrest Capital Management's Ionis Pharmaceuticals position peaked at $2.16M in Q1 2022.
  • 339 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.